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Abstract
Purpose This retrospective cohort study aimed to investigate the surgical and neurodevelopmental outcomes (NDO) of infant 
hydrocephalus. We also sought to determine whether these outcomes are disproportionately poorer in post-haemorrhagic 
hydrocephalus (PHH) compared to other causes of infant hydrocephalus.
Methods A review of all infants with hydrocephalus who had ventriculoperitoneal (VP) shunts inserted at Great Ormond 
Street Hospital (GOSH) from 2008 to 2018 was performed. Demographic, surgical, neurodevelopmental, and other clinical 
data extracted from electronic patient notes were analysed by aetiology. Shunt survival, NDO, cerebral palsy (CP), epilepsy, 
speech delay, education, behavioural disorders, endocrine dysfunction, and mortality were evaluated.
Results A total of 323 infants with median gestational age of 37.0 (23.29–42.14) weeks and birthweight of 2640 g (525–
4684 g) were evaluated. PHH was the most common aetiology (31.9%) and was associated with significantly higher 5-year 
shunt revision rates, revisions beyond a year, and median number of revisions than congenital or “other” hydrocephalus 
(all p < 0.02). Cox regression demonstrated poorest shunt survival in PHH, related to gestational age at birth and corrected 
age at shunt insertion. PHH also had the highest rate of severe disabilities, increasing with age to 65.0% at 10 years, as well 
as the highest CP rate; only genetic hydrocephalus had significantly higher endocrine dysfunction (p = 0.01) and mortality 
rates (p = 0.04).
Conclusions Infants with PHH have poorer surgical and NDO compared to all other aetiologies, except genetic hydrocepha-
lus. Research into measures of reducing neurodisability following PHH is urgently required. Long-term follow-up is essential 
to optimise support and outcomes.
Keywords Intraventricular haemorrhage · Hydrocephalus · Neonates · Ventriculoperitoneal shunts · Neurodevelopmental 
outcome
Introduction
Infant hydrocephalus is often associated with developmen-
tal delay and multiple comorbidities [1, 2]. Both surgical 
and neurodevelopmental outcomes (NDO) have been shown 
to vary depending on the aetiology of hydrocephalus, with 
mixed findings in the literature in terms of ventriculoperito-
neal (VP) shunt failure rates [3–7]. The importance of meas-
uring NDO, rather than surgical outcomes only, in paediatric 
hydrocephalus, has been emphasised [8, 9]. As most studies 
are retrospective and not constrained to infant hydrocepha-
lus alone, separating the effects of the hydrocephalus from 
the underlying pathology can be difficult. Additionally, the 
variation between studies on the influence of hydrocephalus 
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aetiology on NDO is a possible reflection of the heterogene-
ity of the underlying disorders [5].
Post-haemorrhagic hydrocephalus (PHH), which occurs 
following intraventricular haemorrhage (IVH) of prematu-
rity, is hypothesised to be associated with poorer outcomes 
than other aetiologies. In addition to the raised intracranial 
pressure (ICP) and distortion of developing neural tracts 
caused by hydrocephalus, pro-inflammatory cytokines and 
free radicals from iron due to haemoglobin breakdown cause 
toxicity and brain injury [10, 11]. Prematurity is also an 
independent risk factor for poor NDO and has been associ-
ated with high rates of cerebral palsy (CP), epilepsy, and 
visual impairment [12, 13]. Premature neonates with VP 
shunts have higher rates of shunt infection and obstruction 
secondary to immature immune systems and high cerebro-
spinal fluid (CSF) protein levels and red blood cells [14–16].
This retrospective cohort study aims to evaluate the 
surgical and NDO of infant hydrocephalus and to investi-
gate whether PHH has disproportionately poorer outcomes 
compared to other hydrocephalus aetiologies. This will help 
provide prognostic information for clinicians and families 




This retrospective cohort study is reported according to 
STROBE guidelines (checklist available in Supplementary 
Information 1) and was registered as a service evaluation 
with the Great Ormond Street Hospital (GOSH) Clinical 
Audit Department [17].
Inclusion criteria
Any primary VP shunt insertion at GOSH within the first 
year of life, between January 2008 and January 2018, was 
eligible for inclusion. There were no exclusion criteria. 
Patients were identified using a prospectively collected 
neurosurgical operative database.
Data collection
Demographic, surgical, neurodevelopmental, and other clini-
cal data were extracted from the electronic health record 
system. Data for all patients were collected until death, loss 
to follow-up, or the end of the data collection period; the 
last date of follow-up was recorded for each patient to allow 
analysis which accounts for follow-up time.
The aetiology of hydrocephalus was classified into PHH 
(infants born < 37 weeks with IVH diagnosed on cranial 
ultrasound), neural tube defects (NTDs, including mye-
lomeningoceles and encephaloceles), congenital (including 
aqueduct stenosis, brain cysts, and other complex congeni-
tal brain malformations), genetic (X-linked hydrocephalus, 
craniofacial abnormalities, and other suspected genetic 
syndromes), or “other” hydrocephalus. The “other” group 
combined miscellaneous aetiologies with low patient num-
bers and included infection, tumours, trauma, term IVH, and 
unknown causes.
Surgical variables included the use of a temporising 
neurosurgical procedure (TNP) and the method used, cor-
rected age at VP shunt insertion, type of shunt, shunt com-
plications, and number of, and time to any, shunt revisions. 
Where an infected shunt was replaced by a drain prior to 
re-insertion, removal and re-insertion were counted as one 
revision, and the revision date recorded was the removal 
date of the infected shunt. NDO scores were assigned by 
one author (MM), using the scale developed by Resch et al. 
(Table 1), using data from developmental clinic notes, neu-
rosurgical reviews, and paediatric follow-up [18]. NDO was 
reported at 1, 2, 5, and 10 years, corrected for prematurity. 
Only infants who had reached the age of each assessment 
were scored for that time point.
In addition to NDO, clinical outcomes including CP, 
epilepsy, speech delay, type of education for children who 
had reached school age (mainstream, supported, or special 
schooling), behavioural disorders, endocrine dysfunction, 
Table 1  Neurodevelopmental outcome scale developed by Resch et al. [18]
Only cerebral visual impairments and sensorineural hearing losses attributable to hydrocephalus were included in NDO scores. Seizure control 




0 Normal for corrected age, no neurological abnormalities
1 Slight developmental delay, mild neurological abnormalities including mild hypertonia/hypotonia, abnormal coordination, isolated 
hyperreflexia, nystagmus, or strabismus
2 Disabilities like mono-, di-, and hemiparesis, mild visual or hearing impairment, well-controlled seizures, and/or mild learning 
disability
3 Severe disabilities like tri- or quadriparesis, blindness, deafness, poorly controlled seizures, and/or severe learning disability
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and mortality (including age and cause of death) were 
recorded. Children who died before any clinical outcomes 
could be excluded were removed from the analysis of that 
clinical outcome, and infants lost to follow-up were excluded 
from mortality analysis. For cases where outcomes were 
likely influenced by concomitant pathology, a sensitivity 
analysis, which excluded those infants, was conducted.
Statistical analysis
A quantitative analysis was performed using SPSS version 
26.0. Categorical data were summarised as frequencies and 
percentages; as numerical variables were non-parametric, 
median and range were used. Chi-squared tests compared 
categorical variables between aetiology groups where 
expected frequency counts were ≥ 5 and Fisher’s exact test 
where counts were < 5. Ordinal data were analysed using 
the chi-squared test for trend and numerical data using the 
Kruskal–Wallis test. Where significant differences (p < 0.05) 
existed between aetiology groups, pairwise comparisons 
were adjusted for multiple testing using Bonferroni’s cor-
rection (p < 0.0125).
Shunt survival across aetiology groups was evaluated by 
Cox regression, and the effect of aetiology on NDO and 
other clinical outcomes was explored with ordinal, binary, 
and multinomial logistic regression. In multivariate regres-
sion, for each outcome variable studied, a set of potential 
confounders identified from the literature was selected for a 
priori inclusion in the final model, and the remaining poten-
tial predictors were then entered into the model using Back-
ward (Wald) elimination (threshold of significance p < 0.05). 
PHH was the reference group for all regression analyses.
Results
Patient demographics
A total of 323 infants met the study’s inclusion criteria. 
Infants lost to follow-up, either due to death (n = 30) or 
discharge from follow-up (n = 21), were included in the 
study until death or discharge only. Median follow-up was 
6.46 years (0.02–13.22) for all included infants. The most 
common aetiologies of hydrocephalus were PHH of prema-
turity (n = 103, 31.9%), myelomeningocele (n = 36, 11.1%), 
and term IVH (n = 29, 9.0%) (Table 2).
The baseline characteristics of the cohort are described by 
aetiology (Table 3). Males were more frequent in all aetiol-
ogy groups, with no significant differences in sex between 
groups (p = 0.54). Significantly, more infants were preterm 
in the PHH group than all other aetiologies, with a lower 
median gestational age of 27 weeks (p < 0.01) and corre-
spondingly lower birthweights (p < 0.01). Most PHH infants 
had grade IV (54.3%) or grade III (27.2%) IVH. Between 
2008 and 2012, intervention on PHH infants was only con-
sidered for clinical evidence of raised ICP; between 2013 
and 2018, intervention was undertaken earlier, based on a 
ventricular index at the 97th centile plus 4 mm, according to 
the Levene chart [19]. Forty-two (40.8%) PHH infants had a 
TNP prior to VP shunt insertion.
Surgical outcome
Surgical procedures
The median corrected age at VP shunt insertion was 1 day 
before term-equivalence in the PHH group, which was 
Table 2  Aetiologies of hydrocephalus
Other genetic syndromes combined all infants who had a genetic 
diagnosis of hydrocephalus, or for whom the genetics team highly 
suspected a genetic aetiology, but the precise syndrome had yet to be 
identified at the time of the study. Examples included Joubert syn-
drome, CHARGE syndrome, Walker-Warburg syndrome, Aicardi 
syndrome, and Galloway-Mowat syndrome. Other congenital brain 
malformations were complex congenital malformations with no obvi-
ous genetic cause, including holoprosencephaly, hydranencephaly, 
hemimegalencephaly, schizencephaly, septo-optic dysplasia, and 
Dandy Walker malformation. Term IVH was treated as a separate 
entity to PHH of prematurity. The pathophysiology of the brain injury 
in these neonates is different from that in preterm IVH; there is no 
germinal matrix injury, no periventricular infarction, and brain devel-
opment is at a later stage. Management was also different; if there 
was acute hydrocephalus, infants who suffered term IVH underwent 
external ventricular drainage rather than insertion of a VSGS or an 
access device. When necessary, they underwent VP shunt insertion as 
soon as the intraventricular blood resolved
Frequency, n (%)
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significantly younger than genetic, congenital, and “other” 
hydrocephalus (p < 0.01). Most infants (90.1%) had fixed 
pressure valves, with only 13 (4.0%) having programmable 
valves; the distribution of shunt type was different across 
groups (p = 0.01; Table 4).
Shunt revisions
Neither 1-year revision rate nor number of revisions in 
the first year was different between aetiologies (p = 0.11, 
p = 0.10 respectively). However, revision rate > 1  year, 
number of revisions > 1 year, 5-year revision rate, and total 
number of revisions at 5 years were significantly different 
between groups (p = 0.02, p = 0.03, p = 0.03, and p = 0.02, 
respectively), with the rates and medians being highest in 
the PHH group. Revision rates were higher in preterm PHH 
than in term IVH, although this did not reach significance 
(Supplementary Information 2).
Time to first shunt revision
In a univariate analysis of time to shunt failure, PHH had the 
poorest shunt survival, with all other groups having lower 
hazard ratios; only the “other” group was significantly dif-
ferent (Fig. 1). In a multivariate analysis, gestational age 
at birth and corrected age at VP shunt insertion were the 
significant factors affecting shunt survival; when other pre-
dictors were kept constant, every week’s increase in gesta-
tional age at birth decreased the hazard of shunt revision by 
6.9% (p = 0.01), and every week’s increase in corrected age 
at shunt insertion decreased the hazard of revision by 2.0% 
(p = 0.01). Sex, birthweight, and type of shunt valve were 
not included in the multivariate model, as they did not have 
a significant effect on hazard of shunt revision. A higher 
univariate hazard of shunt revision was seen in preterm PHH 
compared to term IVH (Supplementary Information 2).
Shunt complications
The most common reason for shunt revision was obstruction 
(61.3%), followed by infection (14.4%), migration (12.5%), 
CSF leak (7.7%), and over-drainage (1.9%). Reasons for 
revision did not differ significantly between aetiologies. 
Beyond the first year post-shunt insertion, revisions due to 
shunt infection significantly dropped by 8.4% (p = 0.04), 
and those involving obstruction rose by 15.9% (p < 0.01). 
Table 3  Patient characteristics of cohort by aetiology
p values were obtained using the following: chi-squared test: sex, preterm, TNP; Fisher’s exact test: VSGS, VAD, EVD; Kruskal–Wallis test: 
gestational age, birthweight
PHH post-haemorrhagic hydrocephalus, NTDs neural tube defects, TNP temporising neurosurgical procedure, VSGS ventriculosubgaleal shunt, 
VAD ventricular access device, EVD external ventricular drain
˟Percentages do not add up as some infants had multiple temporising interventions
* Parameters that are statistically significant between that aetiology group and PHH
Parameter Frequency (%)/median (range)
Total (n = 323) PHH (n = 103) NTDs (n = 40) Genetic (n = 45) Congenital 
(n = 62)
Others (n = 73) p value
Female 137 (42.4%) 37 (35.9%) 17 (42.5%) 22 (48.9%) 27 (43.5%) 34 (46.6%) 0.54
















Preterm 150 (46.4%) 103 (100.0%) 8 (20.0%)* 14 (31.1%)* 18 (29.0%)* 7 (9.6%)*  < 0.01

















Papile grade: n = 92
Grade I 7 (7.6%)
Grade II 10 (10.9%)
Grade III 25 (27.2%)
Grade IV 50 (54.3%)
TNP˟: 61 (18.9%) 42 (40.8%) 2 (5.0%)* 2 (4.4%)* 2 (3.2%)* 13 (17.8%)*  < 0.01
VSGS 35 (10.8%) 35 (34.0%) 0 (0.0%)* 0 (0.0%)* 0 (0.0%)* 0 (0.0%)* < 0.01
VAD 13 (4.0%) 8 (7.8%) 0 (0.0%) 1 (2.2%) 2 (3.2%) 2 (2.7%) 0.28
EVD 23 (7.1%) 7 (6.8%) 2 (5.0%) 1 (2.2%) 1 (1.6%) 12 (16.4%) 0.01
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Aetiology had no significant effect on the region of obstruc-
tion, with most obstructions involving the proximal catheter 
(70.3%).
Neurodevelopmental outcome
There were significant overall differences in NDO between 
aetiologies at 1 (p < 0.05), 2 (p = 0.01), and 5 (p < 0.01) 
years, while 10-year differences did not reach significance 
due to small sample size (p = 0.14) (Fig. 2). At all four 
time points, the largest percentages of infants scoring a 
“3” (severe disability) occurred in PHH and genetic hydro-
cephalus, increasing sequentially from 26.6% and 25.6%, 
respectively, at 1 year, to 31.5% and 33.3% (2 years), 48.3% 
and 44.0% (5 years), and 65.0% and 45.5% (10 years).
In a multivariate ordinal logistic regression model 
(Table 5), there were significant differences in NDO between 
aetiologies at all time points, apart from 10 years. The odds 
of a poorer NDO, after controlling for gestational age at 
birth, corrected age at shunt insertion, shunt infections, and 
number of revisions up to that time point, remained signifi-
cantly lower in congenital and “other” hydrocephalus than 
in PHH at every time point, except 1 and 10 years when the 
“other” group was no longer significantly different to PHH 
(p = 0.11, p = 0.28, respectively). Outcomes compared to 
PHH were not significantly different in the NTD and genetic 
groups; additionally, none of the a priori predictors had a 
Table 4  Surgical parameters and outcomes by aetiology
As each patient had their shunt in situ for different lengths of time, evaluation of revisions beyond a year of insertion was limited to patients with 
a minimum of 5 years of follow-up post shunt, and only a 5-year follow-up was evaluated. Revision rates are defined as the proportion of patients 
who required VP shunt revisions due to shunt complications. p values were obtained using the following: Chi-squared test: revision rate ≤ 1 year, 
revision rate > 1 year, and 5-year revision rate; Fisher’s exact test: type of VP shunt; Kruskal–Wallis test: corrected age at VP shunt insertion, 
number of revisions ≤ 1 year of shunt, number of revisions > 1 year of shunt, and total number of revisions < 5 years per patient
PHH post-haemorrhagic hydrocephalus, NTDs neural tube defects, VP ventriculoperitoneal
* Parameters that are statistically significant between that aetiology group and PHH
Parameter Frequency (%)/median (range)
Total (n = 323) PHH (n = 103) NTDs (n = 40) Genetic (n = 45) Congenital 
(n = 62)
Other (n = 73) p value
Type of VP 
shunt:
0.01
Fixed pressure 291 (90.1%) 88 (85.4%) 39 (97.5%) 41 (91.1%) 59 (95.2%) 64 (87.7%)
Valveless 19 (5.9%) 13 (12.6%) 0 (0.0%) 0 (0.0%)* 1 (1.6%) 5 (6.8%)
Programmable 13 (4.0%) 2 (1.9%) 1 (2.5%) 4 (8.9%) 2 (3.2%) 4 (5.5%)
Corrected age at 
VP shunt inser-
tion (days)
17.0 (− 88 to 359)  − 1.0 (− 88 to 
238)
1.5 (− 37 to 251) 43 (− 31 to 359)* 28 (− 63 to 324)* 54 (− 18 to 357)*  < 0.01
Excluding those with follow-up < 1 year of shunt insertion:
n = 302 n = 96 n = 39 n = 38 n = 59 n = 70
Revision 
rate ≤ 1 year
102 (33.8%) 36 (37.5%) 16 (41.0%) 16 (42.1%) 19 (32.2%) 15 (21.4%) 0.11
Number of revi-
sions ≤ 1 year of 
shunt
0 (0–4) 0 (0–4) 0 (0–3) 0 (0–3) 0 (0–2) 0 (0–3) 0.10
Excluding those with follow-up < 5 years of shunt insertion:
n =203 n = 59 n = 25 n = 24 n = 41 n = 54
Revision 
rate > 1 year
51 (25.1%) 24 (40.7%) 4 (16.0%) 7 (29.2%) 7 (17.1%)* 9 (16.7%)* 0.02
Number of revi-
sions > 1 year of 
shunt
0 (0–5) 0 (0–5) 0 (0–2) 0 (0–4) 0 (0–2)* 0 (0–4)* 0.03
5-year revision 
rate
95 (46.8%) 37 (62.7%) 10 (40.0%) 13 (54.2%) 16 (39.0%) 19 (35.2%) * 0.03
Total number 
of revi-
sions < 5 years 
per patient
0 (0–9) 1 (0–9) 0 (0–4) 1 (0–4) 0 (0–3)* 0 (0–5)* 0.02
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significant effect on NDO. A direct comparison between 
term IVH and preterm PHH demonstrated significantly 
higher odds of a poorer NDO in preterm PHH at 5 (p = 0.01) 
and 10 years (p = 0.04) (Supplementary Information 2).
Other clinical outcomes
In separate multivariate analyses which controlled for dif-
ferent predictors, including gestational age, corrected age 
at shunt insertion, and shunt revisions (Table 6), significant 
differences were observed between PHH and other aetiolo-
gies in odds of CP (p = 0.01), epilepsy (p < 0.01), speech 
delay (p < 0.01), and mortality (p = 0.01). CP rates were 
highest in PHH (62.6%), while epilepsy rates were highest 
in genetic hydrocephalus (55.2%). In general, the odds of 
most comorbidities were lower for all aetiology groups com-
pared to PHH, except for genetic hydrocephalus which had 
significantly higher odds of endocrine dysfunction (p = 0.01) 
and mortality (p = 0.04). The effects of other predictors in 
the multivariate models are displayed in Table 6; impor-
tantly, each revision < 2 years was significantly associated 
with increased odds of CP by 34.1% (p = 0.04).
In terms of likelihood of attending special school, a uni-
variate analysis demonstrated significantly higher odds in 
PHH than in “other” (p < 0.01), congenital (p < 0.01), and 
NTD-associated hydrocephalus (p = 0.04), with the highest 
proportion of children attending special school in genetic 
(68.0%) and PHH (50.0%) and the highest attending main-
stream school with support in NTDs (60.9%). Behavioural 
disorders did not differ significantly by aetiology (p = 0.23), 
nor did types of behavioural disorders; overall, the common-
est disorders were autism and social communication diffi-
culties (13.0%), sleep difficulties (11.5%), and challenging 
behaviours (10.7%).
The commonest causes of endocrine dysfunction were 
adrenocortical insufficiency (3.4%), growth hormone defi-
ciency (GHD) (3.3%), hypothyroidism (2.2%), and central 
precocious puberty (2.2%); only GHD showed significant 
differences between PHH (0.0%) and genetic hydrocephalus 
(14.7%, p < 0.01). Median age at death was not significantly 
different between aetiology groups (1.41 years, p = 0.69). 
Only one death was shunt-related due to suspected shunt 
infection in a patient with congenital hydrocephalus.
Sensitivity analysis
The sensitivity analysis conducted to separate the effects of 
concomitant pathology on NDO, and other clinical outcomes 
resulted in largely unchanged conclusions (Supplementary 
Information 3).
Fig. 1  Univariate survival function for VP shunt by aetiology group. 
The hazard of overall shunt revision in each aetiology group rela-
tive to PHH can be found next to the relevant Kaplan Meier curve, 
alongside the confidence intervals and p value. Poorest shunt survival 
was observed in PHH; the “other,” congenital, NTD, and genetic 
groups had hazards of shunt revision which were reduced by 43.3% 
(p = 0.01), 30.0% (p = 0.12), 24.2% (p = 0.29), and 10.9% (p = 0.64), 
respectively, relative to PHH. PHH, post-haemorrhagic hydrocepha-
lus; NTDs, neural tube defects; VP, ventriculoperitoneal
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Discussion
PHH comprises a significant proportion of infant hydro-
cephalus, and providing optimal surgical management for 
these infants, with the objective of improving surgical and 
developmental outcome, is crucial. The objective of this 
retrospective cohort study was to present an overall con-
temporary picture of the burden of care, both surgical and 
neurodevelopmental, related to infant hydrocephalus in a 
cohort managed in a single institution, and to underline 
the particular impact of PHH compared to other causes of 
hydrocephalus in infancy. The results demonstrated that 
PHH has the poorest univariate shunt survival and the 
highest rate of severe disability.
Surgical outcome
Shunt failures are common in paediatric hydrocephalus and 
are associated with significant morbidity [7]. In this study, 
shunt survival was poorest in the PHH group, with revision 
rates and number of revisions beyond a year and within 5 years 
significantly higher in PHH than in congenital or “other” 
hydrocephalus. This is consistent with Paulsen et al. who 
demonstrated more frequent revisions in the PHH group than 
Fig. 2  Distribution of NDO scores by aetiology at 1, 2, 5, and 
10 years. The PHH and genetic hydrocephalus groups had the high-
est percentage of “3 s” (severe disability) at all four time points. The 
NTD group scored significantly more “2  s” (disability) and signifi-
cantly fewer “3 s” than PHH at every time (p < 0.01) except 10 years, 
likely due to small sample size (n = 3 NTDs). The congenital and 
“other” hydrocephalus groups had significantly more “0  s” (normal 
outcome) than PHH at every time point (except 10 years for “other”) 
(p < 0.01), and significantly fewer “3 s” than PHH at 5 and 10 years 
(p < 0.01). PHH, post-haemorrhagic hydrocephalus; NTDs, neural 
tube defects; NDO, neurodevelopmental outcome
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other aetiologies, and Notarianni et al. who similarly showed 
higher 5-year shunt failure rates in PHH compared to congeni-
tal and “other” hydrocephalus, with no significant differences 
between PHH and myelomeningoceles [6, 20].
Higher shunt revision rates in the PHH group may be 
explained by the relatively immature immune systems, 
increased CSF protein, variable inflammatory responses to 
CSF blood, small abdominal cavity, and thin skin, which is 
prone to breakdown [16, 21]. Other studies have, however, 
shown conflicting findings; post-infectious hydrocepha-
lus, congenital hydrocephalus, tumours, trauma, and mye-
lomeningoceles have all been associated with the highest 
shunt failure rates in comparable series [3, 7, 22–25]. This 
may be due to the absence of a PHH group in some stud-
ies, differing patient demographics and inclusion criteria, 
or small numbers for some aetiologies in the present study, 
particularly tumours, trauma, and post-infectious hydro-
cephalus [22].
In a multivariate survival analysis, both gestational age 
and corrected age at shunt insertion were independent risk 
factors for shunt failure, in agreement with the literature 
[7, 26, 27]. This reaffirms that prematurity-related factors 
likely contribute to the poor shunt survival seen in PHH. 
This series showed a reduction in the risk of shunt revision 
by 6.9% for every weekʼs increase in gestational age and a 
reduction of 2.0% for every weekʼs increase in corrected 
age at shunt insertion. This suggests that shunt insertion in 
neonates should be deferred if at all possible. PHH infants 
have been shown to have an increased risk of multiple shunt 
failures as they age, suggesting that additional factors such 
as shunt infection may predispose them to multiple shunt 
failures [28, 29].
While not statistically significant, PHH had the highest 
infection rate (17.9% of revisions), likely due to remnants of 
haemorrhagic material and poor immunity [21, 23]. While 
other studies have also demonstrated high infection rates in 
post-infectious hydrocephalus, this subgroup was too small 
within the present study to draw similar conclusions [30]. 
Infections dropped in frequency after the first year of shunt 
insertion, in agreement with Simon et al.’s finding that most 
CSF shunt infections occur within the first 12 months of 
shunt placement [31].
Neurodevelopmental outcome
Severe neurological disability was most prevalent in PHH 
and genetic hydrocephalus, while children with NTDs had 
more mild disabilities in relation to the spinal lesion; chil-
dren in the congenital and “other” hydrocephalus had the 
most normal outcomes. This is consistent with previous 
reports that cognitive impairment, speech and language diffi-
culties, and seizures were most common in PHH, while mus-
culoskeletal problems predominated in myelomeningoceles 
[32]. In PHH and genetic hydrocephalus, the percentage 
of severe disabilities increased with time, up to 65.0% and 
45.5%, respectively, at 10 years. This time-dependent trend 
has been described and underlines the long-term nature of 
the care that these children and young people require [33].
Poor outcomes in PHH may be due to prematurity, ischae-
mic, or inflammatory insults to periventricular brain struc-
tures, subsequent white matter injury, or increased shunt 
complications [32, 34, 35]. Prematurity alone is associated 
with motor and cognitive disability [12]; however, this is 
significantly higher in those infants who also have severe 
IVH and consequent PHH. A large study showed that in 
children born under 28 weeks’ gestation and assessed at 
8 years of age, only 12% had impaired intellectual abil-
ity; in addition, only 24% had motor dysfunction [36]. Our 
cohort only selects premature neonates who also had PHH, 
with consequently poorer outcomes. Genetic hydrocephalus 
has also been associated with neural cell fate alterations in 
the cerebral cortex, suggesting a shared pathogenic process 
Table 5  NDO multivariate regression results
Sex, birthweight, type of shunt valve, and presence or absence of shunt revision by that time point had no significant effect on NDO after adjust-
ing for other predictors so they were excluded from the final multivariate model
PHH post-haemorrhagic hydrocephalus, NTDs neural tube defects, NDO neurodevelopmental outcome
* Parameters that are statistically significant between that aetiology group and PHH (using ordinal logistic regression)
Time point Odds ratio (95% confidence intervals)
PHH NTDs Genetic Congenital Other p value
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with PHH, potentially accounting for the similar outcomes 
of both aetiologies [37].
Other clinical outcomes
Several studies have measured cognition in hydrocephalic 
children using intelligence quotient [38, 39]. Hirsch, how-
ever, suggested that the best guide of functional outcome 
is attendance of mainstream school [40]. In this series, the 
proportion of children attending special school was highest 
in genetic and PHH, supporting the NDO results indicat-
ing poorest outcomes in these aetiologies. The study also 
demonstrated that NTDs had the highest percentage of 
children attending mainstream school with support but sig-
nificantly the lowest attending special school (13.0%), con-
sistent with previous findings that infants with myelomenin-
goceles have, and maintain, improved cognition [39].
This series also observed that the highest CP rates were in 
the PHH group (62.6%), likely due to diffuse post-haemorrhagic 
brain injury and parenchymal infarctions [41]. The number of 
shunt revisions was independently associated with CP and has 
been previously shown to correlate with number of neurologi-
cal impairments [2]. As expected, epilepsy risk was highest 
in genetic hydrocephalus (55.2%) due to associated cortical 
Table 6  Univariate (U) or multivariate (M) regression results for clinical outcomes by hydrocephalus aetiology
Predictors included in the final model varied by clinical outcome are as follows:
CP: birthweight (a priori — gestational age excluded due to high multicollinearity) and number of revisions < 2  years of age (significant in 
model: significantly increased the odds of CP by 34.1% for every revision, p = 0.04)
Epilepsy: gestational age (a priori), corrected age at VP shunt insertion (a priori), shunt revision ≤ 1  year of age (a priori), number of revi-
sions < 1 year of age (a priori), and shunt infection ≤ 1 year of age (a priori)
Speech delay: sex (significant in model: male sex significantly increased odds of speech delay by 49.5%, p = 0.02)
Schooling: there is no multivariate model for schooling as it was not significantly affected by any of the possible predictors included in model 
building, nor were any predictors indicated for a priori inclusion
Mortality: gestational age (a priori) and corrected age at VP shunt insertion (a priori and significant in model: odds of mortality decreased by 
0.6% for every week older the infant was at shunt insertion, p = 0.04)
Behavioural outcome: gestational age (a priori), number of revisions before age 2 (a priori), and sex (a priori and significant in model: male sex 
significantly increased odds of behavioural disorders by 43.3%, p < 0.05)
Endocrine dysfunction: there is no multivariate model as the outcome was not significantly affected by any of the possible predictors, nor were 
any predictors indicated for a priori inclusion
PHH post-haemorrhagic hydrocephalus, NTDs neural tube defects, CP cerebral palsy
˟Median (range)
* Parameters that are statistically significant between that aetiology group and PHH (using logistic regression)
Outcome Odds ratio (95% confidence intervals)/median (range)
PHH NTDs Genetic Congenital Other p value
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malformations, but significantly lower in NTDs (11.1%) than in 
PHH (43.2%) [42]. Odds of speech delay were highest in genetic 
hydrocephalus, and only congenital and “other” hydrocephalus 
had significantly lower odds of speech impairment than PHH, 
as seen in previous literature [32]. The behavioural disorder rate 
for hydrocephalic children in this study was 31.1%, similar to 
the 33% teacher-reported behavioural difficulties rate obtained 
in studies which used standardised questionnaires [43].
The commonest endocrine disorders overall were adren-
ocortical insufficiency, GHD, hypothyroidism, and central 
precocious puberty; these are all associated with anterior 
pituitary dysfunction, supporting the hypothesis that ven-
tricular dilation or raised ICP may disturb the hypothalamic-
pituitary axis, resulting in hypopituitarism [44]. Odds of 
endocrine dysfunction were significantly higher in genetic 
hydrocephalus than in PHH; some congenital conditions 
associated with hydrocephalus, such as midline malforma-
tions, also independently affect the hypothalamo-pituitary 
axis [45]. Finally, mortality was highest in genetic hydro-
cephalus and lowest in NTDs, with a PHH mortality rate 
of 7.3%; this is lower than the rates of 46% reported in the 
literature due to differing study follow-up times and, poten-
tially, improvements in neonatal care over time [46].
Limitations
As this was a retrospective study, it was not possible to 
evaluate children using the Bayley Scales of Infant Devel-
opment [47]. After consideration of multiple developmen-
tal scales, the scale developed by Resch et al. and utilised 
by van Zanten et al. was deemed the most comprehensive 
and reliable due to utilisation of the greatest combination of 
developmental, motor, and sensory sequelae of hydrocepha-
lus (Table 1) [18, 48–52]. There was sufficient information 
from multiple sources to reliably assign outcome scores for 
patients, allowing the collection of NDO data for a large 
population over 10 years. However, while all evaluations of 
NDO were undertaken by the same operator (MM) to ensure 
consistency, the lack of an independent check by another 
reviewer is a limitation of this study. Loss to follow-up, 
death, missing data, and failure to reach the age for spe-
cific assessments also meant that patient numbers in certain 
analyses were smaller than in the original sample.
Although all the patients were treated in the same institu-
tion, there was a modification to the management algorithm 
for PHH from 2013, which included an effort to encourage 
earlier referral of these neonates with earlier implantation 
of TNPs. Timing of the first intervention in PHH is still 
controversial, although some evidence is emerging that early 
treatment may be beneficial [53, 54]. From 2018, a small 
number of neonates also underwent neuroendoscopic lavage 
at the time of VSGS insertion. The protocol for definitive 
VP shunting following PHH, however, remained the same 
throughout the study, with infants with persisting hydroceph-
alus undergoing insertion of a VP shunt at term-equivalent 
age and/or when their weight had reached 2 kg.
As the study was non-randomised, unidentified con-
founders may have biased the results; however, a sensitivity 
analysis controlling for the effects of concomitant pathology 
on outcomes demonstrated largely unchanged conclusions. 
For myelomeningoceles, the effects of the spinal lesion on 
NDO could not be differentiated from the effects of the 
hydrocephalus, although previous research observed more 
frequent motor impairments in myelomeningoceles with 
hydrocephalus than those without [55]. Other clinical out-
comes, such as CP, speech delay, and behavioural disorders, 
were evaluated clinically without using validated prospective 
scales that account for severity. Furthermore, over the long 
study course, the treating neurosurgeons, neonatologists, and 
clinical practices may have varied within the cohort.
Conclusion
This study provides a contemporaneous picture of the bur-
den of care related to infant hydrocephalus, as evaluated in 
our unit over the last 10 years. Surgical outcomes and NDOs 
are worst for PHH and genetic causes of hydrocephalus. In 
most patients, disability worsens with age, underlining the 
importance of long-term neurodevelopmental and neuro-
surgical support and review. Further research to reduce the 
incidence and severity of IVH in premature neonates and 
to minimise their subsequent cognitive impairment in the 
context of PHH is urgently needed.
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